{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093298","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.276408+00:00","generated_at":"2026-05-31T10:51:57.638067+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026","bullets":["Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.","Cash and marketable securities $187.4M as of June 30, 2024; expected to fund operations into H2 2026.","Phase 3 CoMpass trial for small choroidal melanoma continues enrollment globally; target ~100 patients.","Early NMIBC Phase 1 data expected at virtual urologic oncology event in October 2024.","Phase 2 end-of-study data in small choroidal melanoma at Retina Society Annual Meeting Sept 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093298","json":"https://secwatch.observer/filing/0000950170-24-093298.json","markdown":"https://secwatch.observer/filing/0000950170-24-093298.md","text":"https://secwatch.observer/filing/0000950170-24-093298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/0000950170-24-093298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/aura-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:51:57.638067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}